串联自体/异基因造血细胞移植联合硼替佐米维持治疗高危骨髓瘤
这项前瞻性2期试验评估了串联自体/异基因造血细胞移植后硼替佐米维持治疗高危多发性骨髓瘤。31例入组患者中26例(84%)接受HLA相合异基因移植,21例(68%)启动硼替佐米维持。中位随访51个月,24例新诊断高危患者2年和4年无进展生存率分别为71%和75%,总生存率分别为52%和61%。
要点
- 串联自体/异基因移植后硼替佐米维持治疗在新诊断高危骨髓瘤中安全,可能预防疾病进展。
- 该获益未延伸至既往治疗失败后入组的患者。
- 新诊断高危患者2年和4年无进展生存率分别为71%和75%。
核心结论
- 研究提示,对于新诊断高危多发性骨髓瘤患者,串联自体/异基因造血细胞移植后硼替佐米维持治疗是安全的,可能预防疾病进展直至移植物抗骨髓瘤效应完全建立。
- 该获益未延伸至既往治疗失败后入组的患者。
研究设计与样本
- 前瞻性2期试验,入组31例高危多发性骨髓瘤患者。
- 自体移植预处理为美法仑200 mg/m2。
- 异基因移植预处理为非清髓性低剂量全身照射(2 Gy)联合或不联合氟达拉滨(30 mg/m2×3天)。
主要发现
- 31例入组患者中26例(84%)在中位61(范围41-168)天接受HLA相合异基因造血细胞移植。
- 21例患者(68%)在异基因移植后中位79(范围63-103)天启动硼替佐米(1.6 mg/m2静脉或2.6 mg/m2皮下,每14天一次,持续9个月)。
- 中位随访51(范围16-86)个月,基于意向治疗,24例新诊断高危患者2年和4年无进展生存率分别为71%和75%,总生存率分别为52%和61%。
- 7例复发或持续性疾病入组患者2年和4年无进展生存率分别为14%和43%,总生存率分别为14%和29%。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
We evaluated tandem autologous/allogeneic hematopoietic cell transplantation followed by bortezomib maintenance therapy in a prospective phase 2 trial of treatment of high-risk multiple myeloma. The high-dose conditioning regimen for autologous hematopoietic cell transplantation consisted of melphalan 200 mg/m2. The nonmyeloablative conditioning regimen for the allogeneic transplant involved low-dose total body irradiation (2 Gy) with or without fludarabine (30 mg/m2 × 3 days). Among the 31 patients enrolled, 26 (84%) proceeded to HLA-matched allogeneic hematopoietic cell transplantation at a median of 61 (range, 41-168) days following the autologous transplant. Twenty-one patients (68%) started bortezomib (1.6 mg/m2 IV or 2.6 mg/m2 subcutaneously every 14 days for 9 months) at a median of 79 (range, 63-103) days after allogeneic transplantation. With a median follow-up of 51 (range, 16-86) months and based on intention to treat, the 2-year and 4-year progression-free survival and overall survival estimates among 24 newly diagnosed high-risk patients were 71% and 75%, and 52% and 61%, respectively. The 7 patients enrolled with relapsed or persistent disease had a 2-year and 4-year progression-free survival and overall survival rates of 14% and 43%, and 14% and 29%, respectively. These findings suggest that for patients with newly diagnosed high-risk multiple myeloma, bortezomib maintenance therapy after tandem autologous/allogeneic hematopoietic cell transplantation is safe and may prevent disease progression until full establishment of a graft-versus-myeloma effect. This benefit, however, does not extend to patients who enroll after unsuccessful prior therapy. This trial was registered at www.clinicaltrials.gov as #NCT00793572.
引用
- Green DJ, Maloney DG, Storer BE, et al. Tandem autologous/allogeneic hematopoietic cell transplantation with bortezomib maintenance therapy for high-risk myeloma. Blood Adv. 2017. PMID: 29296873. doi:10.1182/bloodadvances.2017010686
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。